# A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors

> **NCT00977795** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Endeavor Health**

## Conditions studied

- Brain Neoplasms

## Interventions

- **DRUG:** 5-aminolevulinic acid

## Key facts

- **NCT ID:** NCT00977795
- **Lead sponsor:** Endeavor Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI moving to Southern Illinois University to start new protocol
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00977795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00977795, "A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00977795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*